<DOC>
	<DOCNO>NCT01659502</DOCNO>
	<brief_summary>The purpose study evaluate efficacy , safety tolerability TL-118 alone combination pancreatic cancer chemotherapy .</brief_summary>
	<brief_title>Investigator 's Initiated Phase II Study Pancreatic Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<criteria>1 . Age least 18 year enrollment . 2 . Locally Advanced Pancreatic Cancer and/or Metastatic Pancreatic Cancer fail respond one two line chemotherapy 3 . The patient histologically cytologically confirm pancreatic cancer . 4 . Patient measurable disease radiological image technique define accord Response Evaluation Criteria Solid Tumors ( RECIST ) . 5 . ECOG performance status ≤ 2 6 . Adequate renal function . 7 . Adequate hepatic function 8 . Adequate bone marrow reserve 9 . Resolution prior therapy acute adverse event . 10 . Patient capable swallowing . 11 . Patient 's Informed Consent . 1 . Hypersensitivity one TL118 active component 2 . Known Glucose6phosphatedehydrogenase deficiency ( G6PD ) . 3 . Known CNS Brain metastases 4 . Patient receive 3 different prior chemotherapy treatment pancreatic cancer 5 . Any significant change treatment within 14 day screen unstable medical condition may affect patient participation evaluation study . 6 . Concurrent use investigational product within 28 day study entry . 7 . Chronic treatment : ( ) immunosuppressive agent systemic corticosteroid , ( b ) patient chronic treatment NSAIDs exception Aspirin daily dose ≤ 100mg . 8 . Use supplement complementary medicines/botanicals , except conventional multivitamin supplement , calcium , selenium soy supplement . 9 . Patients increase risk gastro intestinal bleeding patient know active gastro intestinal ulcer , erosive gastritis varix , confirm gastroscopy perform within one year screening . 10 . Serious uncontrolled coexistent disease likely significantly increase risk associated TL118 therapy ( e.g . severe cardiovascular disease , congestive heart failure , recent myocardial infarction , significant vascular disease , active uncontrolled autoimmune disease , active uncontrolled infection ) . 11 . Patient known historical active infection HIV , hepatitis B , hepatitis C 12 . Serious nonhealing wound , ulcer bone fracture . 13 . Circumstances likely interfere absorption orally administrate drug . 14 . History noncompliance medical regimen coexist condition preclude full compliance study protocol , condition discretion Investigator may preclude safe complete study participation . 15 . Subjects unwilling unable comply study protocol . 16 . Know pregnancy breastfeed woman . 17 . Women child bear potential exercise two method contraception .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Patients</keyword>
</DOC>